- Home
- HUMA vs NNNN Comparison
HUMA vs NNNN Comparison
Compare HUMA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- NNNN
- Stock Information
- Founded
- HUMA 2004
- NNNN 2021
- Country
- HUMA United States
- NNNN Germany
- Employees
- HUMA N/A
- NNNN N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HUMA Health Care
- NNNN Health Care
- Exchange
- HUMA Nasdaq
- NNNN Nasdaq
- Market Cap
- HUMA 367.6M
- NNNN 369.6M
- IPO Year
- HUMA N/A
- NNNN 2025
- Fundamental
- Price
- HUMA $2.47
- NNNN $47.25
- Analyst Decision
- HUMA Strong Buy
- NNNN
- Analyst Count
- HUMA 7
- NNNN 0
- Target Price
- HUMA $13.00
- NNNN N/A
- AVG Volume (30 Days)
- HUMA 3.4M
- NNNN 229.6K
- Earning Date
- HUMA 08-12-2025
- NNNN 01-01-0001
- Dividend Yield
- HUMA N/A
- NNNN N/A
- EPS Growth
- HUMA N/A
- NNNN N/A
- EPS
- HUMA N/A
- NNNN 0.06
- Revenue
- HUMA $517,000.00
- NNNN $8,185,146.00
- Revenue This Year
- HUMA N/A
- NNNN N/A
- Revenue Next Year
- HUMA $896.45
- NNNN N/A
- P/E Ratio
- HUMA N/A
- NNNN $873.07
- Revenue Growth
- HUMA N/A
- NNNN 21.95
- 52 Week Low
- HUMA $1.15
- NNNN $5.18
- 52 Week High
- HUMA $9.79
- NNNN $53.61
- Technical
- Relative Strength Index (RSI)
- HUMA 55.25
- NNNN N/A
- Support Level
- HUMA $2.25
- NNNN N/A
- Resistance Level
- HUMA $2.80
- NNNN N/A
- Average True Range (ATR)
- HUMA 0.19
- NNNN 0.00
- MACD
- HUMA 0.01
- NNNN 0.00
- Stochastic Oscillator
- HUMA 54.55
- NNNN 0.00
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.